Stockscreener 앱 받기
24.40
1.69%
-0.42
시간 외 거래:
24.56
0.16
+0.66%
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - Yahoo Finance
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.com
Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingView
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41 - Moomoo
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds - Investing.com Nigeria
Denali Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking Alpha
DNLI SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Denali Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Denali Therapeutics Q2 Earnings Call Highlights - MarketBeat
Denali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Denali Q2 2026 earnings: AVLAYAH debuts with $3.6 million in revenue - TradingKey
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss - marketscreener.com
Denali Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q2 Revenue $3.6M, vs. FactSet Est of $2.2M - marketscreener.com
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics reports $3.6M in Q2 2026 product revenue, pro forma cash >$1.1B - TradingView
Denali Therapeutics Inc. 2026: Revenue $3.6M, EPS ($0.68) — 10-Q Summary - TradingView
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise - TradingView
Denali Therapeutics (NASDAQ: DNLI) posts Q2 loss and launches AVLAYAH - Stock Titan
BRIEF-Denali Therapeutics Q2 Operating Expenses USD 134.145 Million - TradingView
Denali Therapeutics earnings on deck: First drug sales in focus By Investing.com - Investing.com Nigeria
Denali Therapeutics Inc. (DNLI) Stock Analysis: Investors Eye 48% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Dimensional Fund Advisors LP Boosts Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) to Release Earnings on Thursday - MarketBeat
Denali Therapeutics Inc. $DNLI is ADAR1 Capital Management LLC's 10th Largest Position - MarketBeat
Denali Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Denali Therapeutics sells priority review voucher for $195 million gross proceeds - Bitget
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 - The Manila Times
Denali Therapeutics Inc (DNLI) Cash Flow - TradingKey
Denali sets Aug. 6 webcast on medicines crossing the blood-brain barrier - Stock Titan
Masters Capital Management LLC Sells 400,000 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Denali Therapeutics Inc (DNLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Denali Therapeutics Inc (DNLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DNLI|Denali Therapeutics Inc|Price:24.400|Chg%:-0.420 - TradingKey
Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Institutional Confidence - TradingKey
DNLI Maintained by Morgan Stanley -- Price Target Raised to $36 - GuruFocus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36 - moomoo.com
Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News - Sahm
Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? - Yahoo Finance
Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline - Ad-hoc-news.de
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval? - Yahoo Finance
🤔🤔🤔🤔🤔🤔🤔🤔 - Moomoo
Principal Financial Group Inc. Sells 45,637 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
0.52%
0.07%
자본화:
|
볼륨(24시간):